Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11569742 | 0.85 | CISD1 (0.53) | TDP1CISD1MAPTKDM4EALDH1A1 | |
| SCHEMBL8902085 | 0.81 | CISD1 (0.50) | TDP1CISD1MAPK1MAPTKDM4E | |
| SCHEMBL12316423 | 0.80 | TDP1 (0.45) | TDP1MAPTKDM4EALDH1A1POLB | |
| SCHEMBL380902 | 0.79 | TNF (0.40) | TDP1TNFKDM4EALDH1A1 | |
| SCHEMBL10971694 | 0.78 | TNF (0.50) | TNFMAPK1MAPTKDM4EALDH1A1 | |
| SCHEMBL12316387 | 0.75 | HTT (0.55) | TDP1MAPTKDM4EALDH1A1POLB | |
| SCHEMBL10972729 | 0.74 | TNF (0.51) | TNFMAPK1MAPTKDM4EALDH1A1 | |
| SCHEMBL6439858 | 0.73 | HTR4 (0.60) | ALDH1A1 | |
| SCHEMBL5754001 | 0.73 | TDP1 (0.47) | TDP1MAPK1MAPTKDM4EALDH1A1 | |
| SCHEMBL25142537 | 0.73 | ALDH1A1 (0.49) | TDP1MAPTKDM4EALDH1A1TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476253-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | TDP1 4823/4885TNF 4583/4885CISD1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.